Forty four consecutive patients of AfroCaribbean origin resident in the United Kingdom (UK) were studied, based on a provisional diagnosis of myelopathy of unknown cause, tropical spastic paraparesis (TSP) or multiple sclerosis (MS). Of 30 patients with progressive paraparesis 27 had serum antibodies to HTLV-1 and were classified as having TSP. Fourteen patients fulfilled the criteria for MS and none of 12 tested had HTLV-1 antibodies. All the TSP patients and nine of those with MS were born in the West Indies. Five of the West Indianborn MS patients had migrated to the UK after adolescence but the duration of residence in the UK before symptoms of MS developed was similar to those born in the UK (average 18 years). The features that differentiated MS from TSP patients, apart from HTLV-1 status, included clinical evidence of cranial nerve involvement, more extensive abnormalities on the brain and cervical cord MRI and asymmetry of the VEP latency increase, all of which were more frequent in the MS group. Of the three patients without a diagnosis one, born in the UK, had marked abnormalities on MRI of the brain indistinguishable from those seen in MS.
gestions that people of Caribbean descent born in the UK have a similar prevalence of MS.14 15 In contrast it is said that immigrants from the Caribbean have a low incidence of MS'6 and many neurologists believe that age at immigration is critical in determining the development of the disease since Dean showed"7 that in South Africa MS is rare in European white immigrants who migrated in childhood but more frequent if they entered South Africa after adolescence. While studying TSP patients in London over the past four years we have seen a number of AfroCaribbean patients who had MS and three with myelopathy of unknown cause.
The purpose of this paper is to compare the demographic, clinical and laboratory features of these patients of Afro-Caribbean descent with progressive myelopathies, mostly TSP, with those patients of similar extraction with MS. Secondly, we wanted to ascertain whether these data are consistent with current hypotheses concerning the importance of migration on the liability to develop MS.
Methods
All patients of Afro-Caribbean origin referred to the authors over the previous four years with a diagnosis of TSP, myelopathy of unknown cause or MS were reviewed. All but two were resident in the London area. The diagnostic criteria for MS used were the clinical ones of Poser et al,'" that is, clinically definite (CDMS Al), clinically probable (CDMS Cl) or post-mortem diagnosis (proven MS) . The diagnosis of TSP was made in those patients with a progressive myelopathy in the presence of at least one normal full length myelogram and evidence of HTLV-1 infection.
All patients were questioned and examined by the authors. HTLV-1 antibodies were sought in the blood and CSF by an ELISA and particle agglutination assay and western blotting'9 in all but two patients and the polymerase chain reaction (PCR) to detect integrated HTLV-1 genome using gag and X region primers20 in 11 of the 27 The spinal fluid showed little difference between TSP and MS except in terms of local immunoglobulin synthesis. All the patients with TSP had oligoclonal bands (IgG) compared to only 50% ofthe MS patients. Further- more in the seven TSP patients studied some of the bands contained IgG (5) or IgM (2) HTLV-1 specific immunoglobulins. In some TSP patients oligoclonal bands were found in the serum which never occurred in MS. The CSF protein was elevated in 73% of the MS patients and 39% of those with TSP, while there was a pleocytosis of greater than 5 cells mm-3 in 48% of the TSP patients and 36% of the MS patients. The typical HTLV-1 infected lymphocytes were not sought in the CSF in this study. Two MS patients in severe relapse had cell counts in excess of 100 cells mm-3 on one occasion, whereas no TSP patient had a pleocytosis in greater than 50 cells mm-3. Ten of the 27 TSP patients had positive reagin and FTA tests for Treponemal infection in the blood and one patient with MS, who had previously had syphilis, was also positive. The CSF testing was negative in all patients. Those TSP patients with positive serology tended to be older than those with negative tests (57-4 years versus 52-7 years).
MRI of the brain was carried out in 12 patients with MS and 17 patients with TSP. All the MS patients and 75% of the TSP patients had an abnormal scan. There were, however, marked differences between the two groups (table 4) . First, less than 20% of the TSP patients had abnormal signal return in the brainstem compared with 70% of the MS group. Secondly, the cerebellum was involved in 30% of the MS patients but was invariably spared in the TSP patients. Thirdly, periventricular lesions were always found in the MS patients and in half, the signal return, especially from the trigone and occipital horns, was markedly abnormal while in the TSP patients the changes were mild. Discrete lesions in the central white matter were invaribly found in patients with MS (fig la) but were seen in only two thirds of the TSP group. Finally, although not specifically studied, extensive abnormality of the corpus callosum was confined to the MS patients. It should, however, be emphasised that these differences in the MRI of patients with MS and those with TSP are relative, not absolute; three patients with MS had scans that were no more abnormal qualitatively or quantitatively than the most abnormal scans from TSP patients (compare fig  1 (a) and (b) ).
Cervical cord scans were always normal in the TSP patients but four out of the five MS patients scanned, all of whom had clinical evidence of cervical cord disease, had abnormal cervical cords with one or more plaques apparent (fig 2) . The dorsal cord was atrophic in 60% of the TSP patients and the signal return was either normal or diffusely increased with the exception of one patient where there was a focus of high signal return. As the dorsal cord was scanned in only one MS patient, and this showed focal increase in signal return, comparison with the TSP patients is not possible.
HTL V-I negative paraparesis
Three patients with a provisional diagnosis of TSP were found not to have evidence of HTLV-1 infection (table 5). All had a paraparesis and this was progressive in two, but had remained static for more than 10 years in one. The MRI of the cord and the brain of the one born in the UK (case 1) showed extensive lesions in the cerebral hemispheres and discrete lesions in the posterior fossa of the type commonly seen in MS (fig 3 (a) and (b)). Case 2 had an MRI confined to the cervical and dorsal cord which showed diffusely abnormal signal return while case 3 was not studied.
Discussion
The differential diagnosis of progressive paraparesis, with or without other neurological symptoms, and normal myelography in AfroCaribbean subjects raises a number of important issues. should begin to appear in UK-bom subjects, provided viral transmission occurs in this temperate area, but it may take decades to become apparent given the inefficiency of acquisition. Host factors may also be important in determining whether a patient of Afro-Caribbean origin develops MS or a white European presents with TSP but data presented here, and those of Dean, [1] [2] [3] [4] [5] [6] suggest that, as far as MS is concerned, environmental factors predominate over ethnic ones.
A further point of interest concerning MS in our Afro-Caribbean patients is the young age of onset in the UK-born subjects and the apparent severity of the disease. The mean age of onset in white populations is about 34 years compared with 20 years in our subjects born in the UK. Further, half ofour patients, wherever they were born, were severely disabled within five to eight years, a proportion higher than expected from studies on white populations.28 While this may well be an accident of sampling it is tempting to interpret these data in terms of acquisition of a virus to which the population has never been exposed before; such an event commonly results in severe illness in humans and animals, for example, measles in Eskimaux, myxomatosis in rabbits. If this speculation is correct it supports the concept of geographical restriction of the agent causing MS but does not preclude genetic factors also being important.
Certainty of the diagnosis of MS The diagnosis of MS in our patients seems secure on clinical and investigative grounds but in at least one patient a diagnosis of sarcoidosis was entertained. Sarcoidosis is common in patients of Afro-Caribbean extraction and can simulate MS. There was no positive evidence of sarcoidosis in 13 of the patients studied but in the remaining patient equivocal hilar lymphadenopathy on chest radiograph, and uncertain gallium lacrymal scan and Kveim test gave some support for the diagnosis. This patient, however, died and at necropsy lesions typical of MS were found throughout the spinal cord and brain and there was no abnormality suggesting sarcoidosis in any organ. Thus the diagnosis of sarcoidosis was not sustained.
The only other patient with MS who had another disorder that could have affected the CNS was the patient with a past history of syphilis. However, he had no evidence of CNS syphilis on serological testing, with negative CSF and no evidence of local specific immunoglobulin synthesis.
Differentiation of MSfrom TSP Apart from the invariable occurrence, now by definition, of HTLV-1 antibodies (and the characteristic HTLV-1 leucocytes) in the blood ofTSP patients and their absence in MS, in subjects of Afro-Caribbean extraction there are clinical and other laboratory features that separate the two conditions. In particular in MS the relapsing and remitting nature of the illness, clinical involvement of cranial nerves, the more extensive abnormalities on MRI including focal signal return in the posterior fossa structures and cervical cord, and the asymmetry of the VEP, are all features that are not common, or do not occur, in TSP. No clinical feature, however, other than the relapsing and remitting course, is confined to the MS group and many features such as the CSF abnormalities and derangement of the AEP and SEP are similar in the two conditions. The final arbiter of the diagnosis of TSP against MS is the HTLV-1 status of the patient bearing in mind the small proportion (probably < 2%) of Afro-Caribbean subjects who carry HTLV-1 in the UK. In general, the serum titres of HTLV-1 are high and some of the oligoclonal bands in the CSF are directed against HTLV-1 antigen in TSP, while asymptomatic but infected individuals usually have low serum titres. This makes the detection of HTLV-1 antibodies in high titre in a symptomatic subject fairly secure grounds on which to base a diagnosis of TSP.
The certainty of diagnosis of MS versus TSP is relevant to epidemiological surveys particularly those involving small numbers of patients as in the case of MS in immigrants from the West Indies to the UK. To date HTLV-1 status has not been used fully to screen patients in these surveys, including the most recent, but two of the TSP (HTLV-1 positive) patients in our study were 
